Treatments in Development
There has been a surge in the development of treatments for MS over the last two decades. Currently, there are 18 disease-modifying therapies approved by Health Canada. The development of new treatments is a time-consuming and expensive process, and there is no guarantee as to whether a treatment under trial will be approved by Health Canada. This emphasizes the importance of stimulating research that will uncover new therapeutic targets for MS. Here are some treatments in the pipeline.
Emerging Treatments for RRMS
Emerging Treatments for Progressive MS
| Masitinib | Phase III |
| Tolebrutinib (PPMS) | Phase III |
| Tolebrutinib (non-active SPMS) | Phase III Completed |
| Fenebrutinib (PPMS) | Phase III |
| Frexalimab (non-active SPMS) | Phase III |
| Simvastatin | Phase III Completed |
| IMU-838 | Phase II |
| Lipoic Acid | Phase II Completed |
Disclaimer: MS Canada is an independent, voluntary health agency and does not approve, endorse or recommend any specific product or therapy but provides information to assist individuals in making their own decisions. For specific information and advice, please consult your personal physician. Read our full privacy policy.